The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Type 2 DiabetesOverweightDisordered Eating Behaviors

Interventions

DRUG

Semaglutide

Semaglutide will be administered through 12 weeks.

DRUG

standard of care

Patients not assigned to receive semaglutide will receive standard of care.

Trial Locations (1)

UH Sestre milosrdnice, Zagreb

All Listed Sponsors

collaborator

University of Zagreb School of Medicine

UNKNOWN

lead

University Hospital Sestre Milosrdnice

OTHER

NCT06243536 - The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter